Anavex Life Sciences Corp (AVXL)

[Investor2014]

Thanks for this find TTT.

Interesting with the high focus on whether "ANAVEX2-73 (blarcamesine) can safely travel through the body to the final destination in parts of the brain most affected by Parkinson’s disease, which will help us determine if this new drug can help people with Parkinson’s disease".

We know A2-73 does reach the mouse brain with S1R occupancy vs. dose seemingly linear until a plateau.

We know that high contraction of A2-73 is key to efficacy, but we puzzle with why it seems dose vs. concentration is not a linear function in humans.

This small study seem clearly aimed at figuring that out before embarking on, dare I say, a pivotal P3.